SCHEMBL902188

SCHEMBL902188

CC(C)c1nc2ccnn2c(O)c1Cc1ccc(F)c(Cl)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 3/20 0.37
CCR5 P51681 3/20 0.37
MAPKAPK2 P49137 8/20 0.35
CDK2 P24941 6/20 0.35
PDE4B Q07343 5/20 0.34
PDE4D Q08499 5/20 0.34
PDE4A P27815 4/20 0.33
PDE4C Q08493 4/20 0.33
CHEK2 O96017 1/20 0.33
CDK1 P06493 1/20 0.33
CSNK1D P48730 1/20 0.33
CDK5 Q00535 1/20 0.33
MAPKAPK3 Q16644 1/20 0.33
ROCK2 O75116 1/20 0.33
MAPK9 P45984 1/20 0.33
GSK3B P49841 1/20 0.33
MAP2K1 Q02750 1/20 0.33
MAPKAPK5 Q8IW41 1/20 0.33
KDM5A P29375 1/20 0.32
KDM5B Q9UGL1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL902007 0.91 PDE4B (0.37) CCR2CCR5PDE4BPDE4DPDE4A
SCHEMBL902137 0.90 GCGR (0.35) CCR2CCR5CDK2CDK1
SCHEMBL901553 0.90 CCR2 (0.46) CCR2CCR5PDE10A
SCHEMBL15274719 0.88 CRHR1 (0.34) CCR2CCR5
SCHEMBL902571 0.86 CCR2 (0.38) CCR2CCR5PDE4BPDE4DPDE4A
SCHEMBL902731 0.85 CCR2 (0.42) CCR2CCR5CDK2PDE4BPDE4D
SCHEMBL902490 0.85 PDE2A (0.37)
SCHEMBL902427 0.84 CCNT1 (0.33) CDK2CDK1CDK5
SCHEMBL902696 0.83 MAPKAPK2 (0.40) MAPKAPK2CDK2PDE4BPDE4DPDE4A
SCHEMBL902260 0.82 MAPKAPK2 (0.40) CCR2CCR5MAPKAPK2CDK2CHEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
EP-2621928-A1 7-HYDROXY-PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS Proximagen Limited (GB) 2013-08-07 EP disclosed
WO-2012041817-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS CCR2, CCR5, CCR1 CCR2 1/4885CCR5 2/4885MAPKAPK2 1066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.